MARKET

VRNA

VRNA

Verona Pharma
NASDAQ
16.73
+0.23
+1.36%
Opening 09:30 03/28 EDT
OPEN
16.60
PREV CLOSE
16.50
HIGH
16.73
LOW
16.60
VOLUME
3.47K
TURNOVER
0
52 WEEK HIGH
23.81
52 WEEK LOW
11.83
MARKET CAP
1.35B
P/E (TTM)
-24.3840
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VRNA last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at VRNA last week (0311-0315)?
Weekly Report · 03/18 10:12
Weekly Report: what happened at VRNA last week (0304-0308)?
Weekly Report · 03/11 10:10
Strong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial Strategy
TipRanks · 03/08 12:56
Verona Pharma Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones · 03/04 12:19
HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Benzinga · 03/04 12:09
Buy Rating Affirmed on Verona Pharma Ahead of Ensifentrine’s Expected FDA Approval and Strong Financial Standing
TipRanks · 03/04 11:29
Weekly Report: what happened at VRNA last week (0226-0301)?
Weekly Report · 03/04 10:12
More
About VRNA
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Webull offers Verona Pharma PLC - ADR stock information, including NASDAQ: VRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRNA stock methods without spending real money on the virtual paper trading platform.